In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment right up until illness progression or even the participants are unable to tolerate the study drugs. Possible new ways with the diagnosis and treatment of AML. (A) https://abbv-744brd4inhibitorcanc13467.59bloggers.com/32376526/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies